PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
Boehringer Ingelheim signs option to acquire Trutino Biosciences 15 June 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data 04 March 2022
EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements 13 December 2021
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches 27 September 2021
Europe's largest initiative launches to accelerate therapy development for COVID-19 and future coronavirus threats 27 August 2020
New consortium EUbOPEN will provide tools to unlock disease biology 09 June 2020
Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases 10 January 2020
Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing 31 October 2019
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients 30 August 2019
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies 13 August 2019
Boehringer Ingelheim acquires AMAL Therapeutics, significantly enriching its cancer immunology portfolio with novel cancer vaccines platform 16 July 2019
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta® 11 June 2019
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program 10 May 2019
Independent large real-world study comparing NOACs in AF-patients 16 April 2019
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics 05 April 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD 28 March 2019
Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials 13 February 2019
Boehringer Ingelheim initiates a collaborative partnership with Science 37 to accelerate patient centricity in the development of novel therapies 08 January 2019
Boehringer Ingelheim inaugurates new centre for agile working methods 31 October 2018
Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India 16 October 2018

Page 1 of 5

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
  • End
  1. You are here:  
  2. Home
  3. Boehringer Ingelheim

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2025 PharmaNews.eu. All Rights Reserved.